Rapid adenoviral transduction of freshly resected tumour explants with therapeutically useful genes provides a rationale for genetic immunotherapy for colorectal cancer

Gene Therapy

Volumn 5, Issue 7, 1998, Pages 869-879

  Diaz, R M ^a   Todryk, S ^b   Chong, H ^b   Hart, I R ^a   Sikora, K ^c   Dorudi, S ^d   Vile, R G ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Adenoviral vectors; Colorectal cancer; Cytokines; Immunotherapy

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; THYMIDINE KINASE;

ADENOVIRUS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; COLORECTAL CANCER; CONTROLLED STUDY; EXPLANT; EXPRESSION VECTOR; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; METHODOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; SUICIDE GENE;

ADENOVIRIDAE; ANIMALIA; HERPES; MURINAE; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0031851606     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300690     Document Type: Article

References (66)

1. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 13: 399-415.
2. Forni G et al. Molecular approaches to cancer immunotherapy. Cyto Mol Ther 1995; 1: 225-248.
3. Simons JW et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997; 57: 1537-1546.
4. Gansbacher B et al. Clinical protocol: a pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma. Hum Gene Ther 1992; 3: 677-690.
5. Patel PM et al. Generation of interleukm-2-secreting melanoma cell populations from resected metastatic tumors. Hum Gene Ther 1994; 5: 577-584.
6. Cascinelli N, Foa R, Parmiani G. Clinical protocol: active immunisation of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I-II study. Hum Gene Ther 1994; 5: 1059-1064.
7. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997; 18: 175-182.
8. Durrant LG et al. Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7. Cancer Res 1994; 54: 4837-4840.
9. - T cells recognize a peptide corresponding to a common mutation (13Gly → Asp). Int J Cancer 1994; 56: 40-45.
10. Kim JA et al. Expansion of mucin-reactive T-helper lymphocytes from patients with colorectal cancer Cancer Biother 1995; 10: 115-123.
11. Ransom JH et al. Identification of colon tumor-associated antigens by T cell lines derived from tumor-infiltrating lymphocytes and peripheral blood lymphocytes from patients immunized with an autologous tumor cell/bacillus Calmette-Guerin vaccine. Int J Cancer 1993; 54: 734-740.
12. Tsang KY et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87: 982-990.
13. Conry RM et al. Immune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res 1994; 54: 1164-1168.
14. Di-Giorgio A et al. The influence of tumor lymphocytic infiltration on long-term survival of surgically treated colorectal cancer patients. Int Surg 1992; 77: 256-260.
15. Sensi M, Parmiani G. Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. Immunol Today 1995; 16: 588-595.
16. Maeurer MJ et al. Human intestinal V81+ lymphocytes recognize tumor cells of epithelial origin. J Exp Med 1996; 183: 1681-1696.
17. Rajasekar R, Sim GK, Augustin A. Self heat shock and γδ T-cell reactivity Proc Natl Acad Sci USA 1990; 87: 1767-1771.
18. Yoo YK et al. Tumor-infiltrating lymphocytes from human colon carcinomas. Functional and phenotypic characteristics after long-term culture in recombinant interleukin 2 (see comments). Gastroenterology 1990; 98: 259-268.
19. Horn SS, Rosenberg SA, Topalian SL. Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion. Cancer Immunol Immunother 1993; 36: 1-8.
20. Tsushima H et al. High levels of transforming growth factor β 1 in patients with colorectal cancer: association with disease progression Gastroenterology 1996; 110: 375-382.
21. Gastl GA et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression, Int J Cancer 1993; 55: 96-101.
22. Burg C et al. Leukaemia inhibitory factor derived from rat colon carcinoma cells increases host susceptibility to tumour growth. Cytokine 1995; 7: 784-792.
23. Kubota Y et al. Local immunity and metastasis of colorectal carcinoma. Dis Colon Rectum 1992; 35: 645-650.
24. O'Connell J, O'Sullivan G, Collins JK, Shanahan F. The Fas Counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-1082.
25. Matsuda M et al. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 1995; 61: 765-772.
26. Vile RG, Chong H. Immunotherapy: combinatorial molecular immunotherapy - a synthesis and suggestions. Cancer Metast Rev 1996; 15: 351-364.
27. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
28. Huang AYC et al. Role of bone marrow derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961-965.
29. Huang AY et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA 1996; 93: 9730-9735.
30. Zhang J, Russell SJ. Vectors for cancer gene therapy. Cancer Metast Rev 1996; 15: 385-401.
31. Vile RG. Tumour specific gene expression. Semin Cancer Biolo 1994; 5: 429-136.
32. Hurford JRK, Dranoff G, Mulligan RC, Tepper RI. Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nat Genet 1995; 10: 430-435.
33. Vile RG et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994; 54: 6228-6234.
34. Dalgleish A. The case for therapeutic vaccines. Melanoma Res 1996; 6: 5-10.
35. Jaffee EM et al. High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res 1993; 53: 2221-2226.
36. Leimig T et al. High efficiency transduction of freshly isolated human tumor cells using adenoviral interleukin-2 vectors. Hum Gene Ther 1996; 7: 1233-1239.
37. Tung C et al. Rapid production of interleukin-2 secreting tumor cells by herpes simplex virus-mediated gene transfer: implications for autologous vaccine production. Hum Gene Ther 1996; 7: 2217-2224.
38. Cavallo F et al. Protective and curative potential of vaccination with interleukin-2 gene transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res 1993; 53: 5067-5070.
39. Jaffee EM et al. Use of murine models of cytokine secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. J Immunother 1995; 18: 1-9.
40. Dorudi S, Northover JA, Vile RG. Gene transfer therapy in cancer. Br j Surg 1993; 80: 566-572.
41. Hellstrom KE, Hellstrom I, Chen L. Can co-stimulated rumor immunity be therapeutically efficacious? Immunol Rev 1995; 145: 123-145.
42. Moolten FL. Drug sensitivity {'suicide') genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1: 279-287.
43. Tapscott SJ et al. Gene therapy of rat 9L gliosarcoma by transduction with selectable genes does not require drug selection. Proc Natl Acad Sci USA 1994; 91: 8185-8189.
44. Armstrong CA et al. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res 1996; 56: 2191-2198.
45. Levitsky HI. The best cytokine for the job. Nature Med 1997; 3: 126.
46. Porgador A et al Anti-metastatic vaccination of tumour bearing mice with IL-2 gene-inserted tumour cells. Intl J Cancer 1993; 53: 471-477.
47. Fakhrai H et al. Cytokine gene therapy with interleukin-2 transduced fibroblasts: effects of IL-2 dose on antitumor immunity. Hum Gene Ther 1995; 6: 591-601.
48. Schmidt W et al. Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sci USA 1995; 92: 4711-4714.
49. Chong H, Hutchinson G, Hart IR, Vile RG. Expression of costimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity. Hum Gene Ther 1996; 7: 1771-1779.
50. Sethna MP et al. A negative regulatory function of B7 revealed in B7-1 transgenic mice. Immunity 1994; 1: 415-421.
51. Barba D, Hardin J, Sadelain M, Gage FH. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Nail Acad Sci USA 1994; 91: 4348-1352.
52. Caruso M et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993; 90: 7024-7028.
53. Morton DL et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1993; 216: 463-482.
54. Tahara H et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995; 154: 6466-6474.
55. Franks L, Hemmings V. A cell line from an induced carcinoma of a mouse rectum. J Pathol 1978; 124: 35-38.
56. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York, 1989.
57. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Adds Res 1990; 18: 3587-3596.
58. Castleden SA et al. A family of bicistronic vectors to enhance both local and systemic antitumour effects of HSVtk or cytokine expression in a murine melanoma model. Hum Gene Ther 1997; 8: 2087-2102.
59. Vile RG, Hart IR. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 1993; 53: 3860-3864.
60. McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 1988; 163: 614-617.
61. Vile RG, Miller N, Chernajovsky Y, Hart IR. A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Therapy 1994; 1: 307-316.
62. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988; 167: 400-406.
63. Airman DG. Analysis of survival times. Practical Statistics for Medical Research. Chapman and Hall: London, 1991, pp 365-395.
64. Chong H et al. Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colonystimulating factor induces a local antitumour response and may generate systemic protective immunity. Gene Therapy 1998; 5: 223-232.
65. Castleden SA et al. A family of bicistronic vectors to enhance both local and systemic anti-tumour effects of HSVtk or cytokine expression in a murine melanoma model. Hum Gene Ther 1997; 8: 2087-2102.
66. Melcher A et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nature Med 1998 (in press).